435 Studies Now Enrolling
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
A study for patients with AL amyloidosis using study drug NEOD001
| Sponsor: | Prothena Therapeutics |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAP5356 |
| U.S. Govt. ID: | NCT02312206 |
| Contact: | Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected by amyloid deposits.
This study is closed
